The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature
- PMID: 28005176
- DOI: 10.1007/s00415-016-8360-4
The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature
Abstract
Background: It has long been known that the majority of patients with multiple sclerosis (MS) display an intrathecal, polyspecific humoral immune response to a broad panel of neurotropic viruses. This response has measles virus, rubella virus and varicella zoster virus as its most frequent constituents and is thus referred to as the MRZ reaction (MRZR).
Objective: Re-evaluation of the specificity of MRZR as a marker of MS.
Methods: Structured review of the existing English-, German- and Spanish-language literature on MRZR testing, with evaluation of MRZR in a cohort of 43 unselected patients with MS and other neurological diseases as a proof of principle.
Results: A positive MRZ reaction, defined as a positive intrathecal response to at least two of the three viral agents, was found in 78% of MS patients but only in 3% of the controls (p < 0.00001), corresponding to specificity of 97%. Median antibody index values were significantly lower in non-MS patients (measles, p < 0.0001; rubella, p < 0.006; varicella zoster, p < 0.02). The 30 identified original studies on MRZR reported results from 1478 individual MRZR tests. A positive MRZR was reported for 458/724 (63.3%) tests in patients with MS but only for 19/754 (2.5%) tests in control patients (p < 0.000001), corresponding to cumulative specificity of 97.5% (CI 95% 96-98.4), cumulative sensitivity of 63.3% (CI 95% 59.6-66.8) (or 67.4% [CI 95% 63.5-71.1] in the adult MS subgroup), a positive likelihood ratio of 25.1 (CI 95% 16-39.3) and a negative likelihood ratio of 0.38 (CI 95% 0.34-0.41). Of particular note, MRZR was absent in 52/53 (98.1%) patients with neuromyelitis optica or MOG-IgG-positive encephalomyelitis, two important differential diagnoses of MS.
Conclusion: MRZR is the most specific laboratory marker of MS reported to date. If present, MRZR substantially increases the likelihood of the diagnosis of MS. Prospective and systematic studies on the diagnostic and prognostic impact of MRZR testing are highly warranted.
Keywords: Antibody index; Behçet’s disease; Cerebrospinal fluid; Connective tissue disorders; Herpes simplex virus; MRZ reaction; Measles virus; Multiple sclerosis; Neuroborreliosis Aquaporin-4-IgG-positive neuromyelitis optica MOG-IgG-positive encephalomyelitis; Rubella virus; Varicella zoster virus.
Similar articles
-
Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis.Mult Scler. 2024 Nov;30(13):1598-1608. doi: 10.1177/13524585241279645. Epub 2024 Oct 8. Mult Scler. 2024. PMID: 39377663 Free PMC article.
-
The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity?J Neurol Sci. 2009 May 15;280(1-2):98-100. doi: 10.1016/j.jns.2008.08.002. Epub 2008 Nov 28. J Neurol Sci. 2009. PMID: 19041103
-
The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis.BMC Neurol. 2018 Jan 31;18(1):14. doi: 10.1186/s12883-018-1018-3. BMC Neurol. 2018. PMID: 29386006 Free PMC article.
-
Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.J Neurol. 2018 Feb;265(2):239-252. doi: 10.1007/s00415-017-8656-z. Epub 2017 Nov 2. J Neurol. 2018. PMID: 29098417 Review.
-
Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures.J Neuroinflammation. 2019 Feb 28;16(1):51. doi: 10.1186/s12974-019-1425-4. J Neuroinflammation. 2019. PMID: 30819213 Free PMC article.
Cited by
-
Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients.J Neuroinflammation. 2022 Jan 20;19(1):19. doi: 10.1186/s12974-021-02339-0. J Neuroinflammation. 2022. PMID: 35057809 Free PMC article.
-
Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.Hum Vaccin Immunother. 2021 Nov 2;17(11):4345-4362. doi: 10.1080/21645515.2021.1969850. Epub 2021 Oct 20. Hum Vaccin Immunother. 2021. PMID: 34668842 Free PMC article.
-
Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction.Front Neurol. 2023 Mar 24;14:1135392. doi: 10.3389/fneur.2023.1135392. eCollection 2023. Front Neurol. 2023. PMID: 37034091 Free PMC article.
-
Identification of viral-mediated pathogenic mechanisms in neurodegenerative diseases using network-based approaches.Brief Bioinform. 2021 Nov 5;22(6):bbab141. doi: 10.1093/bib/bbab141. Brief Bioinform. 2021. PMID: 34237135 Free PMC article.
-
Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.Cells. 2020 Nov 25;9(12):2543. doi: 10.3390/cells9122543. Cells. 2020. PMID: 33255854 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical